Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

View:
Post by muslix1 on Jan 18, 2023 9:35am

Pfizer

Sorry it's written in French... But basically it says that Pfizer wants to invest in small biothechnologies...
PAUL can surely arrange something afer 35 years of service at Pfizer...
we will know


Pfizer voit des opportunits d’investissement dans les biotechnologies

PHOTO JOHANNA GERON, REUTERS

« Nous sommes sur le march pour acheter des choses, nous nous sommes engags acheter des technologies et des projets qui deviendront des mdicaments », a dit le PDG du gant pharmaceutique amricain Pfizer, Albert Bourla.

(Davos) Le PDG du gant pharmaceutique amricain Pfizer, Albert Bourla, a voqu mercredi des opportunits d’investissement pour les grands laboratoires afin de pallier les difficults de financement que commencent connatre les plus petites socits des biotechnologies.

  •  

Le secteur biotech « a eu des problmes pour trouver des financements, avec les taux d’intrt qui remontent et les autres incertitudes dans le monde, parce que ce sont des investissements haut risque. Ils ont des problmes pour financer leurs tudes », a-t-il soulign lors d’un vnement organis par le Wall Street Journal Davos, en marge d’une runion du Forum conomique mondial.  

« Les plus petites entreprises sont compltement dpendantes des marchs financiers », contrairement de grands groupes comme Pfizer qui ont les moyens de s’autofinancer. « Pour oprer dans les quelques prochains mois, ils ont besoin que quelqu’un les soutienne financirement. Et il y en a 5000 aux tats-Unis », a-t-il poursuivi.

« C’est le moment de pouvoir aider les biotechs en faisant des partenariats avec elles », a-t-il jug.

Comment by Wino115 on Jan 18, 2023 11:54am
Part of the process they need to get through with whatever data they have on the Phase1 trial for Sort1+ and whatever else they may add to it (or not) is what Qwerty and JFM have said in the past --is there enough evidence there to show validity to the construct of the peptide, the target expression, the theorized internalization and MOA, understanding the limitations of a Phase1, to attract ...more  
Comment by PinnacleX on Jan 18, 2023 12:01pm
The delusionals here are at it again LOL.  Paul with his 35 years a t Phizer  is gonna arrange something lol.  Failed CEO and a failed company that has lied to investors is gonna partner up with Phizer.  So many better companies out there in the states then this Piece of s it comany, yes it happening. 
Comment by palinc2000 on Jan 18, 2023 12:25pm
While I am certain that Paul has made a lot of friends at Pfizer during the 35 yr period he worked there we dont know how amicable his departure was and one must know that when a member of higher management leaves a large corporation he becomes persona non grata!Dont  expect any favor from PFE
Comment by jfm1330 on Jan 18, 2023 2:20pm
One way that would allow to restart the phase I on TH1902 is to forget the baket trial, identify the best cancer type where they think it could be effective based on the data they have. Then, test potential patients for enrollment for real high sortilin overexpression, modify the dosing regimen to whatever they think would be better. Do this very small trial and see what happen. In other words ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities